Success Metrics

Clinical Success Rate
94.4%

Based on 17 completed trials

Completion Rate
94%(17/18)
Active Trials
1(5%)
Results Posted
88%(15 trials)
Terminated
1(5%)

Phase Distribution

Ph not_applicable
1
5%
Ph phase_1
2
10%
Ph phase_2
11
52%
Ph phase_4
1
5%
Ph early_phase_1
1
5%
Ph phase_3
5
24%

Phase Distribution

3

Early Stage

11

Mid Stage

6

Late Stage

Phase Distribution21 total trials
Early Phase 1First-in-human
1(4.8%)
Phase 1Safety & dosage
2(9.5%)
Phase 2Efficacy & side effects
11(52.4%)
Phase 3Large-scale testing
5(23.8%)
Phase 4Post-market surveillance
1(4.8%)
N/ANon-phased studies
1(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

21

all time

Status Distribution
Active(1)
Completed(17)
Terminated(2)
Other(1)

Detailed Status

Completed17
Terminated1
unknown1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
1
Success Rate
94.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.8%)
Phase 12 (9.5%)
Phase 211 (52.4%)
Phase 35 (23.8%)
Phase 41 (4.8%)
N/A1 (4.8%)

Trials by Status

terminated15%
unknown15%
withdrawn15%
completed1781%
recruiting15%

Recent Activity

1 active trials
Showing 5 of 21
recruitingphase_2

Rilonacept in Subjects With Cardiac Sarcoidosis

NCT06660732
completedphase_2

A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis

NCT01903798
completedphase_3

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

NCT03737110
completedphase_2

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

NCT00897715
completedphase_2

Cold Contact Urticaria Treatment With Rilonacept

NCT02171416
View all 21 trials

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT06660732Phase 2

Rilonacept in Subjects With Cardiac Sarcoidosis

Recruiting
NCT01903798Phase 2

A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis

Completed
NCT03737110Phase 3

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Completed
NCT00897715Phase 2

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

Completed
NCT02171416Phase 2

Cold Contact Urticaria Treatment With Rilonacept

Completed
NCT01538719Phase 1

IL1-TRAP, Rilonacept, in Systemic Sclerosis

Completed
NCT01801449Phase 2

Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)

Completed
NCT02828033Early Phase 1

Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss

Unknown
NCT01459796Phase 3

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

Terminated
NCT00610363Phase 2

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

Completed
NCT00958438Phase 3

PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

Completed
NCT00856206Phase 3

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

Completed
NCT00855920Phase 3

Study Utilizing Rilonacept in Gout Exacerbations

Completed
NCT01663103Phase 4

Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

Completed
NCT00534495Phase 2

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

Completed
NCT01830699Not Applicable

Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis

Completed
NCT00962026Phase 1

Rilonacept in Diabetes Mellitus Type 1: Safety Study

Completed
NCT00582907Phase 2

Rilonacept for Treatment of Familial Mediterranean Fever (FMF)

Completed
NCT01045772Phase 2

Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)

Completed
NCT00417417Phase 2

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
21